Thursday, 5 November 2026European Markets

VASTNED BELGIUM And XIOR Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(VIANEWS) - VASTNED BELGIUM (VASTB.BR) is among this list of stock assets with the highest dividend rate and return on equity on the Real Estate sector.

Financial Asset Price Forward Dividend Yield Return on Equity
VASTNED BELGIUM (VASTB.BR) €31.00 7.44% 5.59%
XIOR (XIOR.BR) €31.65 4.13% 0.78%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. VASTNED BELGIUM (VASTB.BR)

7.44% Forward Dividend Yield and 5.59% Return On Equity

Vastned Belgium is a public regulated real estate company (RREC), the shares of which are listed on Euronext Brussels (VASTB). Vastned Belgium invests exclusively in Belgian commercial real estate, more specifically in multi-functional retail properties located in the popular shopping cities of Antwerp, Brussels, Ghent and Bruges. The real estate portfolio also comprises high-end retail parks and retail warehouses. A smaller part of the portfolio is invested in hospitality and residential units.

Earnings Per Share

As for profitability, VASTNED BELGIUM has a trailing twelve months EPS of €2.51.

PE Ratio

VASTNED BELGIUM has a trailing twelve months price to earnings ratio of 12.35. Meaning, the purchaser of the share is investing €12.35 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.59%.

Moving Average

VASTNED BELGIUM's worth is above its 50-day moving average of €29.92 and higher than its 200-day moving average of €29.64.

Revenue Growth

Year-on-year quarterly revenue growth grew by 5.5%, now sitting on 19.34M for the twelve trailing months.

More news about VASTNED BELGIUM.

2. XIOR (XIOR.BR)

4.13% Forward Dividend Yield and 0.78% Return On Equity

Xior Student Housing NV is the first Belgian public regulated real estate company (RREC) specialising in the student housing segment in Belgium, the Netherlands, Spain, Portugal, Germany, Poland, Denmark and Sweden. Within this property segment, Xior Student Housing offers a variety of accommodation, ranging from rooms with shared facilities to en-suite rooms and fully equipped studios. Since 2007, as owner-operator, Xior Student Housing has built high-quality, reliable student accommodation for students looking for the ideal place to study, live and relax. A place with that little bit extra, where every student immediately feels at home. Xior Student Housing has been accredited as a public RREC under Belgian law since 24 November 2015. Xior Student Housing's shares have been listed on Euronext Brussels (XIOR) since 11 December 2015. On 31 December 2023, Xior Student Housing held a property portfolio worth approximately EUR 3.21 billion.

Earnings Per Share

As for profitability, XIOR has a trailing twelve months EPS of €1.32.

PE Ratio

XIOR has a trailing twelve months price to earnings ratio of 23.98. Meaning, the purchaser of the share is investing €23.98 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 0.78%.

More news about XIOR.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com